التفاصيل البيبلوغرافية
| العنوان: |
Favorable clinical response and drug retention of anti-IL-6 receptor inhibitor in rheumatoid arthritis with high CRP levels: the ANSWER cohort study |
| المؤلفون: |
Y Nakayama (11424818), M Hashimoto (1401844), R Watanabe (11424821), K Murakami (6338000), K Murata (11424824), M Tanaka (46344), H Ito (1401829), W Yamamoto (5804033), K Ebina (11424827), K Hata (11424830), Y Hiramatsu (11424833), M Katayama (7391966), Y Son (6952046), H Amuro (6952040), K Akashi (11424836), A Onishi (11424839), R Hara (11424842), K Yamamoto (7725152), K Ohmura (5804036), S Matsuda (1401838), A Morinobu (11424845) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Biochemistry, Medicine, Cell Biology, Pharmacology, Biotechnology, Ecology, Immunology, Developmental Biology, Cancer, Science Policy, Mental Health, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, three groups according, phase reactant driven, observational multicentre registry, favourable therapeutic option, answer cohort study, 5 vs 48, 2 vs 67, specific clinical situation, favorable clinical response, high crp levels, baseline crp levels, treat rheumatoid arthritis, ra patients treated, ra patients according, 8 – 18, 6 receptor inhibitor |
| الوصف: |
Currently, biological disease-modifying anti-rheumatic drugs (bDMARDs) with different modes of action [tumour necrosis factor inhibitor (TNFi), interleukin-6 receptor inhibitor (IL-6Ri), or cytotoxic T-lymphocyte antigen 4–immunoglobulin (CTLA4-Ig)] are used in clinical practice to treat rheumatoid arthritis (RA). However, it is unclear which type of bDMARD is the most efficacious for a specific clinical situation. C-reactive protein (CRP) is an acute-phase reactant driven by IL-6 signalling. Here, we aimed to establish whether therapeutic efficacy differs between IL-6Ri and other bDMARDs with alternative modes of action in RA patients according to their CRP level. RA patients treated with bDMARDs were enrolled from an observational multicentre registry in Japan. Patients were classified into three groups according to baseline CRP tertiles. The overall 3 year retention rates of each bDMARD category were assessed. The Clinical Disease Activity Index (CDAI) was also assessed before and 3, 6, and 12 months after bDMARD initiation. A total of 1438 RA patients were included and classified into three groups according to tertiles of baseline CRP levels (CRP 1 , 0–0.3; CRP 2 , 0.3–1.8; CRP 3 , 1.8–18.4 mg/dL). In CRP 3 , the overall 3 year drug retention rates were significantly higher for IL-6Ri than for TNFi and CTLA4-Ig (77.5 vs 48.2 vs 67.3, respectively). No significant difference was evident in terms of CDAI 12 months after bDMARD initiation in CRP 1 –CRP 3 . IL-6Ri may be a favourable therapeutic option over TNFi and CTLA4-Ig in RA patients with high CRP levels. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/journal_contribution/Favorable_clinical_response_and_drug_retention_of_anti-IL-6_receptor_inhibitor_in_rheumatoid_arthritis_with_high_CRP_levels_the_ANSWER_cohort_study/16610321 |
| DOI: |
10.6084/m9.figshare.16610321.v1 |
| الاتاحة: |
https://doi.org/10.6084/m9.figshare.16610321.v1 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.638E919C |
| قاعدة البيانات: |
BASE |